• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract cancer: phase 3 KEYNOTE-966 trial in progress

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Pembrolizumab in combination.pdf
    Size:
    81.31Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Vogel, A.
    Finn, R.
    Kelley, R.
    Furuse, J.
    Edeline, J.
    Ren, Z.
    Su, S.
    Malhotra, U.
    Siegel, A.
    Valle, Juan W
    Affiliation
    Hannover Medical School, Hannover, Germany
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    Background Biliary tract cancer (BTC) is a rare and heterogeneous malignancy comprising intrahepatic cholangiocarcinoma (CCA), extrahepatic CCA, and gallbladder cancer. Surgery is potentially curative in patients with early disease, but recurrence is common. Combination chemotherapy with gemcitabine and cisplatin is the current standard of care for advanced BTC in most regions as well as S-1 therapy in Japan. Pembrolizumab has demonstrated modest but durable antitumor activity in patients with BTC as monotherapy and improved survival when used in combination with platinum-based chemotherapy in other oncologic indications. KEYNOTE-966 (NCT04003636) is a randomized, double-blind, phase 3 trial evaluating pembrolizumab or placebo plus gemcitabine and cisplatin in patients with advanced BTC. Trial design Eligible patients are ≥18 years old with histologically confirmed metastatic or unresectable BTC, measurable disease per RECIST v1.1, an ECOG performance status of 0 or 1, and adequate organ function. Patients who have received prior systemic therapy for advanced disease, or prior therapy with an anti-PD-1/PD-L1/PD-L2 or CTLA-4 agent, and those with a history of pneumonitis, HIV infection, or central nervous system metastases will be excluded. Patients with past or ongoing HCV or controlled HBV infection are eligible per protocol-defined criteria, provided they do not have dual active HBV and HCV infection at study entry. Approximately 788 patients will be randomly assigned 1:1 to pembrolizumab 200 mg or placebo IV every 3 weeks in combination with gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 IV on days 1 and 8 of every 3-week cycle. Cisplatin will be given for a maximum of 8 cycles; gemcitabine will be given until progression, unacceptable toxicity, or withdrawal. Treatment with pembrolizumab/placebo will be continued for up to 35 cycles (∼2 years of treatment) or until progression, unacceptable toxicity, or withdrawal. Patients will be stratified by region (Asia, non-Asia), stage (locally advanced, metastatic), and tumor origin (gallbladder, intrahepatic, extrahepatic). Imaging will be performed every 6 weeks through week 54, and every 12 weeks thereafter. Adverse events will be monitored throughout the study and for 30 days after treatment (90 days for serious adverse events). Co-primary endpoints are progression-free survival (PFS) per RECIST v1.1 by blinded independent central review (BICR) and OS. Secondary endpoints are objective response rate (ORR) and duration of response (DOR) per RECIST v1.1 by BICR, and safety. Exploratory endpoints are disease control rate (DCR) per RECIST v1.1 by BICR; PFS, ORR, DOR, and DCR per immune-modified RECIST; PFS and ORR per RECIST v1.1 by BICR; and health-related quality of life (by EORTC QLQ-C30, EORTC QLQ-BIL21, and EuroQol EQ-5D-5L). Recruitment began in September 2019 and is underway in 19 countries.
    Citation
    Vogel A, Finn R, Kelley R, Furuse J, Edeline J, Ren Z, et al. P-99 Pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract cancer: phase 3 KEYNOTE-966 trial in progress. Annals of Oncology. 2020;31:S122.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/623316
    DOI
    10.1016/j.annonc.2020.04.181
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2020.04.181
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2020.04.181
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.